Your questions about lung cancer screening, answered
Lung cancer is the leading cause of cancer death in the United States. Screening saves lives — but most people who qualify don't know they do. We've answered the most common questions below.
Lung Cancer Basics
Lung cancer is a disease in which malignant cells form in the tissues of the lung. It is the leading cause of cancer death in the United States for both men and women. While smoking is the primary cause, lung cancer can develop in people who have never smoked. Risk factors include cigarette, pipe, or cigar smoking; secondhand smoke exposure; radon gas (the second most common cause after smoking); air pollution; occupational exposures to asbestos or other chemicals; and personal or family history of lung cancer.
Lung cancer is the second most common cancer in the US and the leading cause of cancer death. Approximately 229,000 new cases are diagnosed each year, and roughly 125,000 Americans die from it annually - more than breast, colon, and prostate cancers combined. 1 in 17 Americans will be diagnosed with lung cancer in their lifetime. Every 2.2 minutes, someone in the US receives a lung cancer diagnosis.
The overall 5-year survival rate for lung cancer is approximately 29.7% - but this number varies dramatically based on when cancer is caught. When found early (localized, stage I–II), the 5-year survival rate rises to 64.7%. When caught late (distant metastasis), it drops to just 9%. Unfortunately, only about 27% of lung cancers are diagnosed at an early stage. This is exactly why screening matters - detecting cancer before symptoms appear dramatically improves outcomes.
The highest-risk individuals are current and former smokers, particularly those with heavy smoking histories. Additional risk factors include: radon gas exposure in the home (test your home - the EPA recommends this for everyone); occupational exposure to asbestos, arsenic, chromium, or diesel fumes; a personal or family history of lung cancer; chronic obstructive pulmonary disease (COPD); and long-term secondhand smoke exposure. Race also plays a role - Black men have the highest lung cancer incidence rate in the US.
Pack-years measure the total amount of cigarettes someone has smoked over their lifetime. You calculate it by multiplying packs per day by years smoked. For example: 1 pack per day for 20 years = 20 pack-years; 2 packs per day for 10 years = 20 pack-years. Current USPSTF screening guidelines require a minimum 20 pack-year history to qualify for annual low-dose CT screening. This metric helps identify people at highest risk who will benefit most from screening.
Yes. Approximately 10–15% of lung cancer cases occur in people who have never smoked, making it the 6th leading cause of cancer death among non-smokers alone. These cases are typically linked to radon gas, secondhand smoke, air pollution, occupational exposures, or family history. If you have never smoked but have significant risk factors, talk to your doctor - screening may still be considered on a case-by-case basis even though current guidelines target smokers and former smokers.
Significant disparities exist in lung cancer outcomes. Black Americans, low-income individuals, and those in rural communities are less likely to be diagnosed at an early stage, less likely to receive curative treatment, and more likely to die from lung cancer than white and higher-income patients - even when controlling for stage at diagnosis. Access to screening is a major driver of these disparities. That is why Oatmeal Health focuses specifically on bringing screening to Federally Qualified Health Centers (FQHCs) serving underserved communities.
Who Should Be Screened
LDCT stands for Low-Dose Computed Tomography. It is a specialized CT scan that takes detailed cross-sectional images of your lungs using significantly less radiation than a standard diagnostic CT scan - about one-fifth the dose. A computer combines hundreds of X-ray images taken from different angles to create a detailed 3D picture of your lungs that radiologists review for any abnormalities, such as nodules. LDCT is quick (typically under 10 minutes), painless, non-invasive, and requires no injections or contrast dye.
The U.S. Preventive Services Task Force (USPSTF) updated its screening guidelines in 2021, giving lung cancer screening a Grade B recommendation. The updated criteria: ages 50–80, at least a 20 pack-year smoking history, and currently smoking or having quit within the past 15 years. These guidelines expanded eligibility significantly from the 2013 version (which required age 55+ and 30 pack-years) - increasing the eligible population by approximately 87% and including more women and minority patients who tend to develop lung cancer with lower smoking exposures.
Yes, significantly. The landmark National Lung Screening Trial (NLST) showed that LDCT reduced lung cancer mortality by 20% compared to chest X-ray. LDCT detected 57% of cancers at an early stage compared to only 39% with chest X-ray. Unlike X-rays, LDCT creates 3D cross-sectional views that reveal small nodules that are invisible on a flat X-ray image. Chest X-rays and sputum cytology tests are not recommended for routine lung cancer screening by any major medical organization.
According to USPSTF guidelines, screening should be discontinued when: you turn 81 years old; you have not smoked for more than 15 years; or you develop a health problem that substantially limits your life expectancy or your ability or willingness to have curative lung surgery. Continuing to screen when the benefits are unlikely to outweigh the risks is not recommended. Your doctor will help you make this decision based on your overall health and individual circumstances.
Quitting smoking is the single most important thing you can do to reduce your lung cancer risk - but former smokers remain at elevated risk for many years after quitting. That is why the USPSTF recommends screening for anyone who quit within the past 15 years. Studies show former smokers benefit from screening just as much as current smokers. If you quit less than 15 years ago and meet the other criteria, you should still be screened annually. After 15 years of not smoking, you no longer meet the screening criteria.
Annual (yearly) screening is recommended for all eligible individuals. Consistent annual screening is important because cancer can develop or grow significantly within a year. If a nodule is detected, your radiologist may recommend more frequent follow-up scans at 3 or 6 month intervals depending on the nodule's size and characteristics. Once a nodule has been monitored and confirmed as stable, you typically return to annual screening.
The Screening Process
Preparation for LDCT lung cancer screening is minimal. You can eat and drink normally before the exam - no fasting is required. You should wear comfortable, loose-fitting clothing without metal zippers or underwire, as you may be asked to change into a gown. Leave jewelry and metal accessories at home. Tell your doctor ahead of time about any recent CT scans, as your facility may want to factor in prior radiation exposure. Importantly, there is no contrast dye or injection involved, so no allergy pre-treatment is needed.
You will lie on a motorized table that slides through a large, ring-shaped machine (the CT scanner). The technologist will position you with your arms above your head. The scan itself typically takes less than 10 minutes - and the actual image-acquisition time is under 30 seconds. You will be asked to hold your breath briefly (about 6 seconds) while images are captured, to reduce motion blur. The machine makes a soft humming sound. There is no pain, no injections, and no loud noise like an MRI. Most patients describe the experience as straightforward and uneventful.
LDCT uses significantly less radiation than a standard diagnostic CT scan - about one-fifth the dose. The effective radiation dose from a single LDCT scan is approximately 1.5 millisieverts (mSv), which is comparable to about 6 months of natural background radiation that everyone is exposed to from the environment. For high-risk individuals, the benefit of early cancer detection far outweighs the small theoretical risk from this level of radiation. Major medical organizations, including the American Cancer Society and USPSTF, have concluded that the benefit-to-risk ratio strongly favors annual screening for eligible patients.
CT scanners are much more open than MRI machines. The ring opening is wide - typically 70 centimeters in diameter - and the table only passes partway through. You can usually see out both ends of the machine throughout the scan. Most patients who are claustrophobic find LDCT tolerable because the scan is so short (under 10 minutes total). If you have significant anxiety, tell your doctor or the technologist before your appointment. In some cases, a mild anti-anxiety medication can be prescribed. Breathing techniques and keeping your eyes closed can also help during the brief scan.
A board-certified radiologist - often with specialized thoracic or chest radiology training - reads your scan and prepares a report. Results are typically available within 1 to 2 weeks. Your ordering physician will contact you to review the results and explain next steps. Many health systems also make results available through a patient portal. If anything urgent is found, you may be contacted sooner. If you haven't heard from your doctor within two weeks, it's appropriate to call and follow up.
Lung cancer screening must be performed at an ACR (American College of Radiology) designated lung cancer screening center to ensure quality standards are met. These centers follow established protocols for image acquisition, radiologist interpretation, and follow-up recommendations. You can find an accredited center near you using the ACR's facility locator at acr.org. Your primary care doctor, FQHC, or community health center can also provide a referral. Oatmeal Health partners with FQHCs to connect patients in underserved communities to accredited screening programs.
In most cases, yes. Medicare requires a written order from a physician, physician assistant, or nurse practitioner, along with a shared decision-making visit before your first screening. This visit ensures you understand the benefits, limitations, and potential harms of screening before proceeding. Most private insurance plans also require a physician referral. However, some community health programs - including those supported by Oatmeal Health at FQHCs - are designed to streamline this process so that eligible patients can access screening quickly without navigating complex referral pathways on their own.
Results and Next Steps
Your radiologist reports results using the Lung-RADS (Lung Imaging Reporting and Data System) scoring system, developed by the American College of Radiology. Lung-RADS scores range from 0 to 4: Category 1 means no nodules found, return next year. Category 2 means findings with a very low likelihood of malignancy, continue annual screening. Category 3 means a probably benign nodule, short-interval follow-up scan in 6 months. Category 4A and 4B mean suspicious findings with increasing levels of concern, requiring additional imaging or tissue sampling. Your doctor will explain what your specific score means for your situation.
A pulmonary nodule is a small, rounded growth in the lung - typically defined as less than 3 centimeters in diameter. The vast majority of nodules detected on screening LDCT are benign (non-cancerous). They are often caused by past infections (like pneumonia or histoplasmosis), scar tissue, or small lymph nodes. In the National Lung Screening Trial, about 96% of positive screening results - meaning a nodule was found - turned out not to be cancer. Finding a nodule is not a diagnosis; it is a finding that prompts careful monitoring to ensure it doesn't change over time.
The Fleischner Society guidelines provide radiologists and clinicians with evidence-based recommendations for managing incidentally detected nodules. Follow-up depends on nodule size, composition (solid vs. subsolid), and patient risk factors. For example: solid nodules smaller than 6mm in low-risk patients typically require no follow-up at all; nodules 6–8mm may need a 6–12 month follow-up CT; nodules larger than 8mm are assessed with contrast CT, PET scan, or tissue sampling. Subsolid (ground-glass) nodules are managed differently because they can represent slow-growing adenocarcinomas that behave very differently from solid tumors. Your radiologist and pulmonologist will select the appropriate protocol for your specific finding.
A false positive occurs when a scan detects something that requires follow-up but turns out not to be cancer. In the NLST trial, approximately 96.4% of positive results in the LDCT group were false positives. This is a known limitation of lung cancer screening. While false positives can cause anxiety and lead to additional imaging or, rarely, an invasive procedure, most are resolved through non-invasive follow-up scans rather than biopsies or surgery. The 2021 USPSTF guidelines and the Lung-RADS system were both designed to reduce unnecessary follow-up by refining how suspicious findings are categorized. The shared decision-making visit required before first screening includes discussion of false positive risk.
If your scan shows a finding suspicious for cancer, your doctor will refer you to a pulmonologist (a lung specialist) or a thoracic surgeon. Additional steps typically include a PET scan to assess whether cancer has spread, and a tissue biopsy to confirm the diagnosis. Biopsies are most commonly done using a bronchoscope (a thin tube inserted through the airway) or a CT-guided needle through the chest wall - both minimally invasive procedures. If cancer is confirmed, your care team will stage the cancer and develop a treatment plan, which may include surgery, radiation, chemotherapy, immunotherapy, targeted therapy, or a combination. The key advantage of screening is that cancer found early is far more likely to be resectable (surgically removable) and curable.
Because LDCT images the entire chest, it may detect findings unrelated to lung cancer. These incidental findings - sometimes called "incidentalomas" - can include emphysema or early COPD, coronary artery calcification (a marker of heart disease risk), aortic aneurysm, enlarged lymph nodes, and other chest abnormalities. Some of these findings are clinically significant and should be evaluated; others are benign and require no action. Your radiologist will note relevant incidental findings in the report, and your doctor will advise whether follow-up is needed. Some patients find that screening leads to the detection of other conditions they were unaware of, which can be an additional benefit of the scan.
Cost and Insurance
Yes. Medicare Part B covers annual LDCT lung cancer screening at no cost - meaning no deductible, no coinsurance, and no copay - for eligible beneficiaries who meet all of the following criteria: age 50 to 77, at least a 20 pack-year smoking history, currently smoking or having quit within the last 15 years, no symptoms of lung cancer, and completion of a shared decision-making visit with a qualifying practitioner before the first screening. Note: Medicare's age cap is 77, slightly below the USPSTF guideline of 80. The shared decision-making visit itself is also covered at no cost.
Under the Affordable Care Act (ACA), most private health insurance plans are required to cover preventive services that receive a Grade A or B recommendation from the USPSTF at no cost to the patient - meaning no copay or coinsurance when you go to an in-network provider. Lung cancer screening received a Grade B recommendation in 2021, meaning it must be covered at no cost sharing by ACA-compliant plans. However, coverage rules can vary: grandfathered plans (those that existed before the ACA) may not be required to cover it, and self-funded employer plans may have different rules. Always verify coverage with your insurer before your appointment.
Medicaid coverage of lung cancer screening varies by state. Unlike Medicare and ACA-compliant plans, Medicaid is not required by federal law to cover LDCT screening without cost sharing. As of recent data, most states cover lung cancer screening through Medicaid, but the specifics - including eligibility criteria, prior authorization requirements, and cost sharing - differ significantly. Some states align with USPSTF criteria; others use older, more restrictive criteria. If you are on Medicaid, contact your state Medicaid program or your managed care plan directly to confirm what is covered and what steps are required to access screening.
If you are uninsured or underinsured, you still have options. Federally Qualified Health Centers (FQHCs) are required to serve all patients regardless of insurance status or ability to pay. FQHCs use a sliding-fee scale based on income, so the cost of a visit - including a referral for screening - is adjusted to what you can afford. Some may have a nominal fee of $20–$40 or less for low-income patients. Additionally, some hospital systems and cancer centers offer free or reduced-cost screening programs, often funded through grants or community benefit programs. Oatmeal Health specifically partners with FQHCs to help connect uninsured and underinsured patients to lung cancer screening.
For most ACA-compliant private insurance plans, prior authorization should not be required for lung cancer screening because it is a mandated no-cost preventive service. However, some insurers - particularly for Medicaid plans or grandfathered plans - may require prior authorization before they will cover the scan. To avoid unexpected costs, confirm with your insurer whether prior authorization is needed, and if so, have your doctor submit the request before scheduling. Make sure the facility you use is in-network and is an ACR-accredited screening center, as using an out-of-network provider can result in cost sharing even for covered services.
The initial annual LDCT screening scan itself should be free under Medicare and most ACA-compliant plans. However, costs can arise in certain situations. If a nodule is found and you require a follow-up diagnostic CT scan (rather than a preventive screening scan), it may be billed as a diagnostic procedure rather than a screening, which means cost sharing may apply. Similarly, biopsies, PET scans, and specialist visits are not covered under the same zero-cost-sharing rules as the preventive screening. The shared decision-making visit is covered at no cost, but if other medical issues are discussed at the same visit, that portion may be billed separately. Always ask your provider upfront whether any part of the visit will be billed as diagnostic rather than preventive.
AI in Screening
Artificial intelligence is being applied across the entire lung cancer screening workflow. On the imaging side, AI-powered computer-aided detection (CAD) tools help radiologists identify and measure pulmonary nodules in LDCT scans with greater consistency and speed. On the clinical side, AI platforms are used to identify eligible patients in electronic health records who haven't been offered screening, automate outreach and shared decision-making support, coordinate referrals between primary care providers and imaging centers, and track whether patients follow through on recommended follow-up scans. Oatmeal Health focuses specifically on this clinical workflow side - using AI to close the gap between eligibility and actual screening.
No. AI in lung cancer screening is designed to assist radiologists, not replace them. Current AI tools function as a second reader or decision-support system. A board-certified radiologist still reviews your scan and signs the final report. AI helps by flagging potential findings for the radiologist to prioritize, measuring nodule size and density with precision, and reducing the chance that a small finding is overlooked. The radiologist applies clinical judgment, contextual knowledge, and accountability that AI cannot replicate. The combination of AI-assisted detection plus expert human review has been shown to improve detection accuracy compared to either alone.
Several FDA-cleared AI tools for lung nodule detection have demonstrated high sensitivity and specificity in clinical studies. For example, studies of leading AI CAD tools have shown sensitivity above 90% for nodules larger than 4mm - the clinically significant threshold. Some studies have found that AI-assisted reading detects more nodules than radiologists reading alone, particularly for small or subtle findings. However, AI tools are not perfect: they can produce false positives (flagging benign structures as nodules) and may miss atypical presentations. This is why AI is positioned as a decision-support tool within a radiologist-led workflow rather than as a standalone diagnostic system.
Oatmeal Health's AI platform is built specifically for Federally Qualified Health Centers (FQHCs) and community health centers serving underserved populations. Our platform analyzes patient data within existing health records to identify individuals who are eligible for lung cancer screening but have not yet been screened - closing the gap between eligibility and action. From there, we support the clinical workflow: helping providers initiate the shared decision-making conversation, coordinating referrals to accredited screening facilities, and tracking follow-through. Our focus is on the populations where the gap is largest: Black Americans, low-income individuals, rural communities, and uninsured patients who have historically been underscreened despite high risk.
Several AI tools for lung nodule detection and characterization have received FDA clearance through the 510(k) pathway as medical devices. FDA-cleared AI tools for lung cancer screening are designed to be used within a radiologist-supervised workflow. Clinical workflow tools like patient identification and care coordination platforms - the type of work Oatmeal Health does - fall under a different regulatory category and are generally deployed as clinical decision-support software rather than diagnostic devices. The distinction matters: AI tools that make or significantly influence a clinical diagnosis are subject to FDA oversight, while tools that support care coordination and workflow are typically classified separately.
This is one of the most promising applications of AI in lung cancer care. Today, only about 20% of eligible high-risk Americans are being screened. The barriers are both clinical (providers don't always know which patients qualify) and systemic (access, referral coordination, follow-through). AI can address both: by automatically identifying eligible patients in health records, by making it easier for busy primary care providers to initiate the screening conversation, and by ensuring that referrals don't fall through the cracks. For FQHCs and community health centers - which often serve the populations with the highest risk and the least access - AI-enabled workflows have significant potential to close the screening gap at scale.
Common Myths
"I quit smoking years ago - I don't need to be screened."
Former smokers remain at significantly elevated risk for lung cancer for many years after quitting. The USPSTF recommends annual screening for anyone who quit within the past 15 years and meets the other criteria. Studies show former smokers benefit from screening just as much as current smokers.
"If I had lung cancer, I would feel it."
Early-stage lung cancer typically causes no symptoms at all. Cough, chest pain, and shortness of breath usually appear only once cancer has grown or spread - at which point it is much harder to treat. This is precisely why screening exists: to detect cancer before symptoms begin, when survival rates are dramatically better.
"Lung cancer only happens to heavy smokers."
About 20% of lung cancer cases occur in people who have never smoked, making lung cancer in non-smokers one of the most common causes of cancer death in the US on its own. Radon gas, secondhand smoke, air pollution, and occupational exposures all contribute to lung cancer risk in non-smokers.
"A chest X-ray is good enough to detect lung cancer."
Chest X-rays cannot detect the small nodules that LDCT can find. The National Lung Screening Trial directly compared the two: LDCT reduced lung cancer mortality by 20% compared to chest X-ray. Flat X-ray images simply cannot show the detail needed to detect early-stage lung cancer. No major medical organization recommends X-rays for routine lung cancer screening.
"If a nodule is found, it probably means I have cancer."
The vast majority of pulmonary nodules are benign. In the NLST trial, roughly 96% of positive screening results turned out not to be cancer. Nodules are often the result of past infections, scar tissue, or small lymph nodes. A nodule finding triggers careful monitoring, not automatic diagnosis.
"Lung cancer screening is expensive and not covered by insurance."
Annual LDCT screening is covered at no cost under Medicare and most ACA-compliant private insurance plans for eligible patients. There are no copays, no deductibles, and no coinsurance when done at an in-network, accredited facility. For uninsured patients, FQHCs offer sliding-scale access so cost is not a barrier.
"There's nothing you can do about lung cancer, so why screen?"
When caught at an early, localized stage, lung cancer has a 5-year survival rate of about 65% - compared to just 9% when caught late. Early-stage lung cancer is highly treatable, often with minimally invasive surgery alone. Screening exists precisely because catching lung cancer early makes a life-saving difference.
Find out if you qualify for free lung cancer screening
If you are between 50 and 80 years old with a 20+ pack-year smoking history and currently smoke or quit within the last 15 years, you may qualify for annual LDCT screening at no cost. Talk to your doctor or visit your nearest FQHC to get started.